Company news
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) news
Every Mirum Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
July 29, 2026
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossific...
June 14, 2026
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accept...
June 4, 2026
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
May 30, 2026
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
May 21, 2026
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
May 12, 2026
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
May 4, 2026
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosi...
May 3, 2026
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
April 29, 2026
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
April 27, 2026
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
March 16, 2026
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
March 5, 2026
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
February 25, 2026
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
February 18, 2026
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in ...
February 5, 2026
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progr...
February 5, 2026
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
January 26, 2026
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
January 12, 2026
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2026
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing...
January 9, 2026
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX
December 19, 2025
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
December 8, 2025
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
December 1, 2025
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
November 25, 2025
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’...
November 7, 2025
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
November 4, 2025
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
October 28, 2025
Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study
September 8, 2025
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
August 6, 2025
Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
July 30, 2025
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer
May 19, 2025
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL
May 9, 2025
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 7, 2025
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
April 30, 2025
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses
April 28, 2025
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation
April 14, 2025
LIVMARLI Now Approved in Japan for ALGS and PFIC
March 27, 2025
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
February 26, 2025
Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)
February 24, 2025
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025
February 19, 2025
Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates
January 13, 2025
Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting
November 14, 2024
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
November 4, 2024
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
October 31, 2024
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
October 10, 2024
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 7, 2024